Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 278.00, up by 5.80 points or 2.13% from its previous closing of Rs. 272.20 on the BSE.
The scrip opened at Rs. 280.00 and has touched a high and low of Rs. 293.90 and Rs. 276.60 respectively. So far 34639 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 532.40 on 12-Jan-2018 and a 52 week low of Rs. 268.00 on 15-Nov-2018.
Last one week high and low of the scrip stood at Rs. 293.90 and Rs. 271.00 respectively. The current market cap of the company is Rs. 7117.72 crore.
The promoters holding in the company stood at 68.11%, while Institutions and Non-Institutions held 8.62% and 23.27% respectively.
Sun Pharma Advanced Research Company (SPARC) has reported top-line results of the pivotal BE study for Paclitaxel Injection Concentrate for Suspension (PICS).
The pivotal BE study was a randomized, open label, two period, single dose, crossover study of PICS and Abraxane in subjects with locally recurrent or metastatic breast cancer.
A total of 142 patients were randomized to characterize the pharmacokinetic (PK) profile of PICS for both unbound and total paclitaxel compared with Abraxane. The study also provided information on the safety profile of PICS. The study met all the required pharmacokinetic endpoints for both unbound and total paclitaxel. There were no new adverse events observed in this study.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
